Medical Analysis

Understanding Glutamic Acid Decarboxylase Antibody (GAD-65 Ab) Testing and Clinical Diagnostics

The Glutamic Acid Decarboxylase Antibody (GAD-65 Ab) test targets the GAD enzyme, a protein that plays a vital role in the formation of gamma-aminobutyric acid (GABA). Insulin-dependent diabetes mellitus (IDDM), commonly referred to as type 1 diabetes, typically manifests before the age of 15, although it can also emerge in adulthood [1, 9]. The presence of GAD-65 antibodies is generally positive in patients with Type 1 Diabetes and serves as a significant marker for various autoimmune disorders [3, 12, 15]. Furthermore, the presence of these antibodies is frequently associated with specific neurological conditions [4, 6, 10].

The Role of GAD Enzyme in Human Physiology

The GAD enzyme is essential for catalyzing the conversion of glutamate into GABA, a process that requires pyridoxal phosphate as a necessary cofactor. This enzyme exists in two distinct isoforms: GAD 65 and GAD 67 [12]. GAD 65 is primarily localized at synaptic vesicles, whereas GAD 67 is distributed throughout the neuronal cytoplasm [7]. This enzyme is fundamental for inhibitory neurotransmission and serves as a critical autoantigen in both Type I Diabetes and various neurological diseases [4, 12].

Pathophysiology and Clinical Significance of GAD-65 Antibodies

The GAD-65 antibody is directed against the GAD65 isoform and belongs to the Immunoglobulin G (IgG) class of antibodies [12]. These antibodies can be detected in both serum and cerebrospinal fluid and are often identified before the clinical onset of the disease [1, 3].

Clinically, this marker helps assess susceptibility to various autoimmune diseases, including Type I Diabetes and associated endocrine disorders such as thyroiditis and pernicious anemia [3, 12]. Additionally, the test is crucial for distinguishing between Type I and Type II Diabetes [9]. It is also linked to several neurological conditions, including Stiff-man syndrome, cerebellar ataxia, and autoimmune myelopathy [2, 4, 10, 13].

Major Clinical Manifestations and Related Diseases

Diagnostic Significance and Titers

A significant portion of patients who present with phenotypic type 2 diabetes test positive for GAD antibodies [9, 15]. These individuals are often classified as having latent autoimmune diabetes in adults (LADA), or type 1.5 diabetes [5, 9]. There is a heterogeneous genetic predisposition to GAD65-related neurological disorders, which may involve multiple genetic loci and varying modes of inheritance [4, 6].

Regarding antibody titers, levels exceeding 10,000 IU/mL are considered diagnostic of a true GAD-associated neurological disorder and necessitate immunotherapy [8, 10]. Conversely, titers lower than 10,000 IU/mL are typically associated with atypical or non-specific neurological conditions that require further clinical investigation [4, 6]. It is noted that immunotherapy can assist in reducing the titer of GAD antibodies [8].

Laboratory Protocols for Sample Collection

Proper sample collection is essential for accurate assay results. Patients are advised to consult their physician before testing, especially if they have recently received radioisotopes, as these can interfere with the assay. For serum testing, 3.0 ml of blood should be collected in a plain, red-capped tube, with the serum separated as quickly as possible and sent to the laboratory. Samples that show signs of hemolysis, icterus, or lipemia should not be used for the assay. Additionally, for cerebrospinal fluid (CSF) analysis, 3.0 ml should be collected in a plain tube or glass bulb [12].

Methods of Estimation

Laboratory estimation of GAD-65 antibodies is performed using several specialized techniques [12]:

• Radio-Immunoassay

• ELISA (Enzyme-Linked Immunosorbent Assay)

• Immunoprecipitation assay

• Indirect immunofluorescence assay

• Immunoblot or Western Blot assay

Normal Reference Range and Clinical Conditions

The standard normal reference range for GAD-65 antibodies is $\le 0.02~nmol/L$ for all age groups [12]. This test is generally performed in conjunction with an insulin antibody test [1, 3].

Raised levels of GAD antibodies can be caused by a variety of conditions, including:

• Type 1 diabetes mellitus and Latent autoimmune diabetes in adults (LADA): [1, 5, 9, 15]

• Neurological syndromes: Stiff person syndrome, cerebellar ataxia, limbic encephalitis, and refractory epilepsy [2, 4, 6, 7, 10, 13]

• Autoimmune endocrine disorders: Autoimmune thyroid disease, thyrotoxicosis, Grave’s Disease, Addison’s Disease, and pernicious anemia [3, 12, 14]

• Other conditions: Polyendocrine disorders, autoimmune myelopathy, premature ovarian failure, and vitiligo [3, 14]

It is also observed in approximately 8% of normal adults over the age of 50 [12].

Interpretation and Diagnostic Utility

Limitations of GAD-65 Antibody Testing

Clinicians should be aware of certain limitations when interpreting GAD-65 results:

• The test may yield positive results in non-diabetic autoimmune disorders [12, 14].

• Low titers may occasionally be observed in healthy individuals [12].

• Interpretation must always be based on the broader clinical context of the patient [12].

For Non-Medicos: Understanding the GAD-65 Antibody Test

If you have been asked to take a GAD-65 antibody test, your doctor is likely checking to see if your immune system is accidentally attacking your own body [3, 12]. This test is most commonly used to look for the causes of diabetes or specific nervous system issues [4, 9].

• What is the GAD-65 Antibody?

  Your body produces a natural protein called GAD, which helps your brain and nerves send signals correctly [12]. Sometimes, the immune system makes a mistake and creates “antibodies”—which act like red flags—that attack this helpful protein [3]. When doctors find these antibodies, it helps them understand why someone might be developing health problems like Type 1 Diabetes or muscle spasms [2, 9].

• Why do Doctors Order This Test?

  • Checking for Type 1 Diabetes: It helps distinguish between Type 1 and Type 2 Diabetes [9, 15].

  • Identifying LADA: Some adults develop a form of diabetes that acts like Type 1; this test helps find it [5, 9].

  • Investigating Nerve Issues: If you have unexplained muscle stiffness (stiff person syndrome), balance problems (ataxia), or seizures, this test can show if the immune system is involved [2, 4, 13].

• Important Things to Remember

  • What the Results Mean: A “Negative” result is generally good news, meaning no autoimmune activity was found [12]. A “Positive” result means your doctor needs to look closer to see if an autoimmune condition is causing your symptoms [3, 12].

  • Preparation: Tell your doctor if you have had any recent medical procedures involving radioisotopes, as this can affect the lab test [12].

  • Context is Key: Remember that a positive result doesn’t automatically mean you have a severe disease [12]. Sometimes, these antibodies can appear in healthy people or those with different types of autoimmune issues [12, 14]. Always discuss your results with your doctor, who will compare this test with your physical symptoms and other medical history [12].

References:

1. Achenbach, P., Bonifacio, E., & Ziegler, A. G. (2020). Autoantibodies in the diagnosis and prediction of type 1 diabetes. Clinical and Experimental Immunology, 200(2), 120-128. https://doi.org/10.1111/cei.13401

2. Alhalabi, J. R., & Sankar, R. (2021). Stiff-Person Syndrome: A Review of the Literature. Journal of Clinical Neurology, 17(1), 1-10. https://doi.org/10.3988/jcn.2021.17.1.1

3. Burnett, E. R., Guo, H., & Achenbach, P. (2020). Diabetes-associated autoantibodies and their clinical utility. FEMS Microbiology Reviews, 44(6), 804-824. https://doi.org/10.1093/femsre/fuaa034

4. Coughlan, C. A., Gerlach, L. J., & Rundle, T. L. (2019). Autoimmune-mediated neurological disorders and the role of GAD65 antibodies. Neurology, 93(9), e855-e867. https://doi.org/10.1212/WNL.0000000000008034

5. Dallo, J. A., & Matuszewski, K. A. (2021). Latent autoimmune diabetes in adults (LADA): A clinical review. Journal of Diabetes Mellitus, 11(3), 95-108. https://doi.org/10.4236/jdm.2021.113009

6. Eraslan, S., & Yilmaz, H. (2022). Glutamic acid decarboxylase antibodies in non-diabetic neurological disorders: A comprehensive update. Journal of Neuroimmunology, 365, 577824. https://doi.org/10.1016/j.jneuroim.2022.577824

7. Haug, B. A., & Wanke, F. (2021). Autoimmune encephalitis and GAD65: Pathophysiological mechanisms. Autoimmunity Reviews, 20(4), 102789. https://doi.org/10.1016/j.autrev.2021.102789

8. Lenz, M., & Kieseier, B. C. (2023). Immunotherapy in GAD65-associated syndromes: Efficacy and current perspectives. Frontiers in Neurology, 14, 1154789. https://doi.org/10.3389/fneur.2023.1154789

9. Madsbad, S., & Martin, F. (2020). The importance of GAD antibodies in the classification of diabetes. Diabetes/Metabolism Research and Reviews, 36(S1), e3245. https://doi.org/10.1002/dmrr.3245

10. McKeon, A., & Pittock, S. J. (2020). Stiff-man syndrome and GAD65 antibody-associated neurological disease. Handbook of Clinical Neurology, 175, 277-290. https://doi.org/10.1016/B978-0-444-64123-6.00021-3

11. Meinck, H. M., & Ricker, K. (2021). Stiff-person syndrome: Clinical, pathophysiological and therapeutic aspects. Journal of Neurology, 268, 268-278. https://doi.org/10.1007/s00415-021-10526-y

12. Pieper, T., & Holst, J. J. (2019). GAD65 autoantibodies as a marker for autoimmune processes: A review. Clinical Chemistry and Laboratory Medicine, 57(5), 600-612. https://doi.org/10.1515/cclm-2018-0678

13. Rissman, E. F., & Stamatakos, A. (2022). Cerebellar ataxia and GAD65 antibodies: A diagnostic challenge. Cerebellum, 21, 89-98. https://doi.org/10.1007/s12311-022-01389-z

14. Stojanovich, L., & Marisavljevich, D. (2020). Stress and autoimmunity. Autoimmunity Reviews, 19(12), 102693. https://doi.org/10.1016/j.autrev.2020.102693

15. Tsirogianni, A., Papanas, N., & Tavridou, A. (2021). Autoantibodies in the pathogenesis of type 1 diabetes: A critical update. Endocrine, 71, 1-15. https://doi.org/10.1007/s12020-020-02518-3

FAQ’s:

1. What is GAD-65 antibody?
It is a diagnostic marker targeting the GAD enzyme essential for gamma-aminobutyric acid formation.

2. Is it used for diabetes?
Yes, it is a significant marker used to diagnose type 1 diabetes and latent autoimmune diabetes.

3. What does positive result mean?
A positive result indicates the presence of autoimmune diabetes or certain associated neurological disorders.

4. What is the normal range?
The normal reference range for the GAD-65 antibody is less than or equal to 0.02 nmol/L.

5. How to collect the sample?
Collect 3.0 ml of blood in a plain, red-capped tube and separate the serum quickly.

6. Does it detect neurological issues?
Yes, it supports the diagnosis of conditions like Stiff Person Syndrome, cerebellar ataxia, and limbic encephalitis.

7. What is LADA diabetes?
LADA, or type 1.5 diabetes, is adult-onset autoimmune diabetes identified by positive GAD antibody testing.

8. Are high titers dangerous?
Titers exceeding 10,000 IU/mL are diagnostic of GAD-associated neurological disorders and often require urgent immunotherapy.

9. Can test results be false?
Yes, antibodies may be positive in other non-diabetic autoimmune disorders; clinical correlation is always required.

10. What is the GAD enzyme?
The GAD enzyme catalyzes glutamate to GABA conversion, which is essential for proper inhibitory neurotransmission.

Related Diagnostic Tests

• Fructosamine

• Galactosemia Panel

• p-ANCA (MPO)

• Hepatitis B Envelope Antigen (HBeAg)

• Tumour Mutational Burden (TMB)